VTP-38543 / AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
VTP-38543 / AbbVie
NCT02655679: An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

Completed
1/2
104
Canada, US
VTP-38543, Vehicle with Transcutol®P, Transcutol®P is Diethylene Glycol Monoethyl Ether, NF., Vehicle without Transcutol®P
Vitae Pharmaceuticals, Inc.
Dermatitis, Atopic
09/16
09/16

Download Options